MetaVia completes last patient visit in extended 24-week Phase 1 Part 3A study of DA-1726
MTVA•MetaVia completed the last patient visit in the extended 24-week Phase 1 Part 3A study of DA-1726. Full data from Parts 3A and 3B are expected in Q1 2027, and a Phase 2 study is planned for the second half of 2027.
1. Study update
MetaVia announced completion of the last patient visit in its extended 24-week Phase 1 Part 3A study of DA-1726. The company expects full data from Parts 3A and 3B in Q1 2027 and plans a Phase 2 study for the second half of 2027.




